Terveystalo Oyj

LSE:0RV1 Stock Report

Market Cap: €1.2b

Terveystalo Oyj Valuation

Is 0RV1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RV1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0RV1 (€9.74) is trading below our estimate of fair value (€22.96)

Significantly Below Fair Value: 0RV1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RV1?

Key metric: As 0RV1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0RV1. This is calculated by dividing 0RV1's market cap by their current revenue.
What is 0RV1's PS Ratio?
PS Ratio0.9x
Sales€1.33b
Market Cap€1.23b

Price to Sales Ratio vs Peers

How does 0RV1's PS Ratio compare to its peers?

The above table shows the PS ratio for 0RV1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.3x
IDHC Integrated Diagnostics Holdings
2.4x19.1%US$228.5m
KOO Kooth
1.1x9.4%UK£61.3m
SPI Spire Healthcare Group
0.6x6.0%UK£887.2m
CVSG CVS Group
0.9x5.5%UK£589.0m
0RV1 Terveystalo Oyj
0.9x3.2%€1.2b

Price-To-Sales vs Peers: 0RV1 is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (1.3x).

Price to Sales Ratio vs Industry

How does 0RV1's PS Ratio compare vs other companies in the European Healthcare Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
0RV1 0.9xIndustry Avg. 0.6xNo. of Companies13PS00.61.21.82.43+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0RV1 is expensive based on its Price-To-Sales Ratio (0.9x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is 0RV1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RV1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: 0RV1 is expensive based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RV1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€9.74
€11.68
+19.9%
4.4%€12.10€10.80n/a4
Nov ’25€10.02
€11.55
+15.3%
3.9%€12.00€10.80n/a4
Oct ’25€9.66
€10.95
+13.4%
4.5%€11.60€10.20n/a4
Sep ’25€10.18
€10.95
+7.6%
4.5%€11.60€10.20n/a4
Aug ’25€10.36
€10.95
+5.7%
4.5%€11.60€10.20n/a4
Jul ’25€8.72
€10.00
+14.7%
4.9%€10.50€9.20n/a4
Jun ’25€8.88
€9.70
+9.3%
6.0%€10.50€9.10n/a4
May ’25€8.72
€9.70
+11.2%
6.0%€10.50€9.10n/a4
Apr ’25€7.54
€9.06
+20.2%
7.5%€10.00€8.00n/a5
Mar ’25€7.20
€9.06
+25.8%
7.5%€10.00€8.00n/a5
Feb ’25€7.94
€9.02
+13.6%
7.9%€10.00€8.00n/a5
Jan ’25€7.73
€9.02
+16.7%
7.9%€10.00€8.00n/a5
Dec ’24€7.28
€9.02
+23.9%
7.9%€10.00€8.00n/a5
Nov ’24€6.70
€9.10
+35.8%
8.1%€10.00€8.00€10.025
Oct ’24€7.56
€9.30
+23.0%
8.0%€10.00€8.00€9.665
Sep ’24€7.86
€9.30
+18.3%
8.0%€10.00€8.00€10.185
Aug ’24€7.34
€9.30
+26.7%
8.0%€10.00€8.00€10.365
Jul ’24€8.26
€9.84
+19.1%
7.2%€11.00€9.00€8.725
Jun ’24€7.99
€9.68
+21.2%
9.3%€11.00€8.40€8.885
May ’24€7.92
€9.44
+19.2%
10.0%€11.00€8.40€8.725
Apr ’24€7.02
€9.30
+32.5%
11.2%€11.00€8.30€7.545
Mar ’24€7.15
€9.30
+30.1%
11.2%€11.00€8.30€7.205
Feb ’24€7.20
€9.04
+25.5%
15.8%€11.00€7.30€7.945
Jan ’24€6.27
€8.59
+37.0%
18.2%€11.00€7.25€7.735
Dec ’23€6.33
€8.59
+35.7%
18.2%€11.00€7.25€7.285
Nov ’23€6.15
€8.59
+39.7%
18.2%€11.00€7.25€6.705

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.05

7D

-4.2%

1Y

4.8%

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.52

7D

-5.4%

1Y

-8.8%

Guerbet

€335.4m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€26.70

7D

-9.6%

1Y

50.0%